MedTrace Logo

Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

NCT03670082 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-11-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the extent to which Lu AF35700 enters the bloodstream following pill intake and the influence of food on the uptake in healthy men and women

Conditions

  • Healthy

Interventions

DRUG

Lu AF35700

20 mg Lu AF35700 single oral dose

DRUG

Lu AF35700 iv

100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-05
Primary Completion
2018-12-21
Completion
2019-01-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03670082 on ClinicalTrials.gov